Literature DB >> 21447427

Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients.

Kathleen J Yost1, David T Eton, Sofia F Garcia, David Cella.   

Abstract

OBJECTIVE: We combined anchor- and distribution-based methods to establish minimally important differences (MIDs) for six Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer scales in advanced-stage cancer patients. STUDY DESIGN AND
SETTING: Participants completed 6 PROMIS-Cancer scales and 23 anchor measures at an initial (n=101) assessment and a follow-up (n=88) assessment 6-12 weeks later. Three a priori criteria were used to identify usable cross-sectional and longitudinal anchor-based MID estimates. The mean standard error of measurement was also computed for each scale. The focus of the analysis was on item response theory-based MIDs estimated on a T-score scale. Raw score MIDs were estimated for comparison purposes.
RESULTS: Many cross-sectional (64%) and longitudinal (73%) T-score anchor-based MID estimates were excluded because they did not meet a priori criteria. The following are the recommended T-score MID ranges: 17-item Fatigue (2.5-4.5), 7-item Fatigue (3.0-5.0), 10-item Pain Interference (4.0-6.0), 10-item Physical Functioning (4.0-6.0), 9-item Emotional Distress-Anxiety (3.0-4.5), and 10-item Emotional Distress-Depression (3.0-4.5). Effect sizes corresponding to these MIDs averaged between 0.40 and 0.63.
CONCLUSIONS: This study is the first to address MIDs for PROMIS measures. Studies are currently being conducted to confirm these MIDs in other patient populations and to determine whether these MIDs vary by patients' level of functioning.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21447427      PMCID: PMC3076200          DOI: 10.1016/j.jclinepi.2010.11.018

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  32 in total

1.  Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches.

Authors:  K J Yost; D Cella; A Chawla; E Holmgren; D T Eton; J Z Ayanian; D W West
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

2.  Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument.

Authors:  Kathleen J Yost; Mark V Sorensen; Elizabeth A Hahn; G Alastair Glendenning; Ari Gnanasakthy; David Cella
Journal:  Value Health       Date:  2005 Mar-Apr       Impact factor: 5.725

Review 3.  Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.

Authors:  Dennis Revicki; Ron D Hays; David Cella; Jeff Sloan
Journal:  J Clin Epidemiol       Date:  2007-08-03       Impact factor: 6.437

4.  The minimal detectable change cannot reliably replace the minimal important difference.

Authors:  Dan Turner; Holger J Schünemann; Lauren E Griffith; Dorcas E Beaton; Anne M Griffiths; Jeffrey N Critch; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2009-10-01       Impact factor: 6.437

5.  Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel.

Authors:  Honghu Liu; David Cella; Richard Gershon; Jie Shen; Leo S Morales; William Riley; Ron D Hays
Journal:  J Clin Epidemiol       Date:  2010-08-05       Impact factor: 6.437

6.  What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

Authors:  David Cella; David T Eton; Diane L Fairclough; Philip Bonomi; Anne E Heyes; Cheryl Silberman; Michael K Wolf; David H Johnson
Journal:  J Clin Epidemiol       Date:  2002-03       Impact factor: 6.437

7.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales.

Authors:  David Cella; David T Eton; Jin-Shei Lai; Amy H Peterman; Douglas E Merkel
Journal:  J Pain Symptom Manage       Date:  2002-12       Impact factor: 3.612

8.  Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa.

Authors:  D L Patrick; D D Gagnon; M J Zagari; R Mathijs; J Sweetenham
Journal:  Eur J Cancer       Date:  2003-02       Impact factor: 9.162

9.  Effect sizes for interpreting changes in health status.

Authors:  L E Kazis; J J Anderson; R F Meenan
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

10.  Three ways to quantify uncertainty in individually applied "minimally important change" values.

Authors:  Henrica C W de Vet; Berend Terluin; Dirk L Knol; Leo D Roorda; Lidwine B Mokkink; Raymond W J G Ostelo; Erik J M Hendriks; Lex M Bouter; Caroline B Terwee
Journal:  J Clin Epidemiol       Date:  2009-06-21       Impact factor: 6.437

View more
  242 in total

1.  Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis.

Authors:  Monique E Hinchcliff; Jennifer L Beaumont; Mary A Carns; Sofia Podlusky; Krishna Thavarajah; John Varga; David Cella; Rowland W Chang
Journal:  J Rheumatol       Date:  2014-11-01       Impact factor: 4.666

Review 2.  Mental health outcomes during colorectal cancer survivorship: a review of the literature.

Authors:  Catherine E Mosher; Joseph G Winger; Barbara A Given; Paul R Helft; Bert H O'Neil
Journal:  Psychooncology       Date:  2015-08-27       Impact factor: 3.894

3.  Relative Prevalence of Anxiety and Depression in Patients With Upper Extremity Conditions.

Authors:  Casey M Beleckas; Melissa Wright; Heidi Prather; Aaron Chamberlain; Jason Guattery; Ryan P Calfee
Journal:  J Hand Surg Am       Date:  2018-02-01       Impact factor: 2.230

4.  Responsiveness of 8 Patient-Reported Outcomes Measurement Information System (PROMIS) measures in a large, community-based cancer study cohort.

Authors:  Roxanne E Jensen; Carol M Moinpour; Arnold L Potosky; Tania Lobo; Elizabeth A Hahn; Ron D Hays; David Cella; Ashley Wilder Smith; Xiao-Cheng Wu; Theresa H M Keegan; Lisa E Paddock; Antoinette M Stroup; David T Eton
Journal:  Cancer       Date:  2016-10-03       Impact factor: 6.860

5.  The Health related Quality of Life of Puerto Ricans during Cancer Treatments; A Pilot Study.

Authors:  Velda J Gonzalez; Susan McMillan; Elsa Pedro; Maribel Tirado-Gomez; Leorey N Saligan
Journal:  P R Health Sci J       Date:  2018-03       Impact factor: 0.705

6.  Health-related profiles of people with lower limb loss.

Authors:  Dagmar Amtmann; Sara J Morgan; Jiseon Kim; Brian J Hafner
Journal:  Arch Phys Med Rehabil       Date:  2015-04-25       Impact factor: 3.966

7.  The Impact of Ostomy on Quality of Life and Functional Status of Crohn's Disease Patients.

Authors:  Maisa I Abdalla; Robert S Sandler; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

8.  Frailty and health-related quality of life in older women with breast cancer.

Authors:  Grant R Williams; Allison M Deal; Hanna K Sanoff; Kirsten A Nyrop; Emily J Guerard; Mackenzi Pergolotti; Shlomit S Shachar; Bryce B Reeve; Jeannette T Bensen; Seul Ki Choi; Hyman B Muss
Journal:  Support Care Cancer       Date:  2018-11-27       Impact factor: 3.603

9.  Different Phenotyping Approaches Lead to Dissimilar Biologic Profiles in Men With Chronic Fatigue After Radiation Therapy.

Authors:  Li Rebekah Feng; Kristin Dickinson; Neila Kline; Leorey N Saligan
Journal:  J Pain Symptom Manage       Date:  2016-08-09       Impact factor: 3.612

10.  PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions.

Authors:  Karon F Cook; Sally E Jensen; Benjamin D Schalet; Jennifer L Beaumont; Dagmar Amtmann; Susan Czajkowski; Darren A Dewalt; James F Fries; Paul A Pilkonis; Bryce B Reeve; Arthur A Stone; Kevin P Weinfurt; David Cella
Journal:  J Clin Epidemiol       Date:  2016-03-04       Impact factor: 6.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.